Greune joins CureVac as COO; plus Azafaros names Ultragenyx vet Portolano as CEO and updates from Tenaya, Ambrx, BioSkryb, HiberCell and more
mRNA company CureVac N.V. (NASDAQ:CVAC) hired Malte Greune as COO. He joins from Sanofi-Aventis Deutschland GmbH, where he served for nine years, most recently as general manager and VP of the cartridges, devices and insulin technology group, responsible for manufacturing sites in Frankfurt. Florian von der Mülbe, co-founder and chief production officer, will resign from the management board to focus exclusively on expansion and accelerated development of The RNA Printer, the company’s mobile and automated product for mRNA vaccines and therapeutics manufacturing. Greune will replace von der Mülbe on the board.
Stefano Portolano has joined Dutch metabolic disorder company Azafaros B.V. as CEO. He was head of Europe at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)...